Euroopa Liit - eesti - EMA (European Medicines Agency)

elanco gmbh - tulatromütsiin - antibakteriaalsed ained süsteemseks kasutamiseks - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. haiguse esinemine karjas tuleb kindlaks määrata enne metafülaktilist ravi. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. haiguse esinemine karjas tuleb kindlaks määrata enne metafülaktilist ravi. the product should only be used if pigs are expected to develop the disease within 2–3 days. lambad: nakkusliku pododermatiidi (suu mädanemine) varajase staadiumi ravi, mis on seotud virulentse dichelobacter nodosus'ega ja vajab süsteemset ravi.

Eesti - eesti - Ravimiamet

farmak international sp. z o.o. - gadoteerhape - süstelahus - 0,5mmol 1ml 60ml 10tk; 0,5mmol 1ml 100ml 1tk; 0,5mmol 1ml 5ml 10tk; 0,5mmol 1ml 10ml 1tk; 0,5mmol 1ml 15ml 1tk; 0,5mmol 1ml 20ml 1tk; 0,5mmol 1ml 100ml 10tk; 0,5mmol 1ml 15ml 10tk; 0,5mmol 1ml 10ml 10tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

tmc pharma (eu) limited - fosdenopterin hydrobromide dihydrate - metal metabolism, inborn errors - muud alimentary seedetrakti ja ainevahetust tooted, - nulibry is indicated for the treatment of patients with molybdenum cofactor deficiency (mocd) type a.

Eesti - eesti - Ravimiamet

sanochemia pharmazeutika gmbh - gadoteerhape - süstelahus - 0,5mmol 1ml 10ml 10tk; 0,5mmol 1ml 20ml 1tk; 0,5mmol 1ml 15ml 1tk; 0,5mmol 1ml 20ml 10tk; 0,5mmol 1ml 10ml 1tk; 0,5mmol 1ml 15ml 10tk

Eesti - eesti - Ravimiamet

ipsen pharma - botulismitoksiin - süstelahuse pulber - 125ühik 1tk

Eesti - eesti - Ravimiamet

croma-pharma gmbh - botulismitoksiin - süstelahuse pulber - 50ühik 6tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastilised ained - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Eesti - eesti - Ravimiamet

teva pharma b.v. - epirubitsiin - süste-/infusioonilahus - 2mg 1ml 10ml 1tk; 2mg 1ml 75ml 1tk; 2mg 1ml 5ml 1tk; 2mg 1ml 25ml 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Euroopa Liit - eesti - EMA (European Medicines Agency)

meda ab - zaleplon - unehäirete ja hoolduse häired - psühhoeptikumid - sonata on näidustatud unetuse raviks, kellel on uinumisraskused. see on näidustatud ainult siis, kui haigus on tõsine, invaliidistumine või üksikisiku ülitundlikkus.